Thus, identification of the novel co-regulator and clarification of the molecular mechanism for modulation of E2/ERα signaling in breast cancer is important to advocate a new therapeutic strategy for ERα-positive breast cancer and endocrine resistance. This evidence concerns the gene ESR1 and breast cancer.